Cargando…

Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 in diabetic individuals

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at increased risk for COVID-19 related morbidity and mortality. Antibody response to COVID-19 vaccine in T2DM patients is not very clear. The present work aims to evaluate the antibody response to the inactivated SARS-CoV-2 vaccine in thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yandong, Shen, Ping, Tao, Yue, Zhang, Wenjun, Xu, Biyun, Bi, Yan, Han, Zhen, Zhou, Yi-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773130/ https://www.ncbi.nlm.nih.gov/pubmed/36568756 http://dx.doi.org/10.3389/fpubh.2022.1025901

Ejemplares similares

Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2
por: Cheng, Yandong, et al.
Publicado: (2022)

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series
por: Zhao, Ting, et al.
Publicado: (2022)

Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study
por: Zhou, Yi-Hua, et al.
Publicado: (2023)

Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China
por: Yang, Peng, et al.
Publicado: (2023)

Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers
por: Bansal, Amit, et al.
Publicado: (2023)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

COVID-19 vaccination coverage among adolescents aged 12–17 years in three provinces of eastern China: A cross-sectional survey, 2021
por: Li, Taishun, et al.
Publicado: (2022)

Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study
por: Ebinger, Joseph E, et al.
Publicado: (2021)

Inactivation and Recovery of High Quality RNA From Positive SARS-CoV-2 Rapid Antigen Tests Suitable for Whole Virus Genome Sequencing
por: Macori, Guerrino, et al.
Publicado: (2022)

Molecular Phylogenesis and Spatiotemporal Spread of SARS-CoV-2 in Southeast Asia
por: Zhu, Mingjian, et al.
Publicado: (2021)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey
por: Valerio-Shewmaker, Melissa A., et al.
Publicado: (2021)

How to reduce the exposure risk of medical staff from SARS-CoV-2 by reducing environmental contamination: Experience from designated hospitals in China
por: Zeng, Cui, et al.
Publicado: (2022)

‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour
por: Waller, Jo, et al.
Publicado: (2020)

Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study
por: Prakash, Om, et al.
Publicado: (2021)

Trends in MERS-CoV, SARS-CoV, and SARS-CoV-2 (COVID-19) Diagnosis Strategies: A Patent Review
por: Nascimento Junior, José Adão Carvalho, et al.
Publicado: (2020)

Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China
por: Sheng, Qilian, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 Assessed by Four Chemiluminescence Immunoassays and One Immunocromatography Test for SARS-Cov-2
por: Cerino, Pellegrino, et al.
Publicado: (2021)

Increasing ventilation reduces SARS-CoV-2 airborne transmission in schools: A retrospective cohort study in Italy's Marche region
por: Buonanno, Giorgio, et al.
Publicado: (2022)

Quantitative SARS-CoV-2 Antibody Screening of Healthcare Workers in the Southern Part of Kyoto City During the COVID-19 Pre-pandemic Period
por: Fujita, Kohei, et al.
Publicado: (2020)

Staffing and Capacity Planning for SARS-CoV-2 Monoclonal Antibody Infusion Facilities: A Performance Estimation Calculator Based on Discrete-Event Simulations
por: Çaglayan, Çaglar, et al.
Publicado: (2022)

Heat-Treated Virus Inactivation Rate Depends Strongly on Treatment Procedure: Illustration with SARS-CoV-2
por: Gamble, Amandine, et al.
Publicado: (2021)

Changes in the epidemiological profile of SARS-CoV-2-positive individuals in Mexico across pandemic waves as an explanation of fatality reduction: a retrospective observational study
por: Gutierrez, Juan Pablo, et al.
Publicado: (2023)

Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico
por: Peña Rodríguez, Marcela, et al.
Publicado: (2023)

Hospital-wide SARS-CoV-2 antibody screening of 4840 staff members in a University Medical Center in France: a cross-sectional study
por: Pierson-Marchandise, Marion, et al.
Publicado: (2022)

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India
por: Singh, Bishnupati, et al.
Publicado: (2023)

SARS-CoV-2 and Plasmodium falciparum Co-Infection in a Returning Traveler
por: Huang, Qian, et al.
Publicado: (2022)

Systems Thinking About SARS-CoV-2
por: Klement, Rainer Johannes
Publicado: (2020)

The Origin of Sars-CoV-2: Why It Matters
por: Vineis, Paolo, et al.
Publicado: (2021)

Laboratory Readiness and Response for SARS-Cov-2 in Indonesia
por: Aisyah, Dewi N., et al.
Publicado: (2021)

SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability
por: Huang, Hong, et al.
Publicado: (2023)

Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January–December 2020
por: Vaughan, Aisling, et al.
Publicado: (2023)

Application of SARS-CoV-2 Serology to Address Public Health Priorities
por: Sherman, Amy C., et al.
Publicado: (2021)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

Public health measures to reduce the risk of SARS-CoV-2 transmission in Canada during the early days of the COVID-19 pandemic: a scoping review
por: Polisena, Julie, et al.
Publicado: (2021)

Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India
por: Thangaraj, Jeromie Wesley Vivian, et al.
Publicado: (2022)

SARS-CoV-2 infections among asymptomatic individuals contributed to COVID-19 cases: A cross-sectional study among prospective air travelers from Ghana
por: Akowuah, Kwasi A., et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 Detection With Nasopharyngeal Swabs
por: Clerici, Bianca, et al.
Publicado: (2021)

The Emergence and Spread of Novel SARS-CoV-2 Variants
por: Yi, Huaimin, et al.
Publicado: (2021)

A Citywide Approach to SARS-CoV2 Testing
por: Broach, John P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v817o5alhs7re1g8vf835f7re4